Back to results
US 12,006,511 B2Granted
Recombinant PD-L1 peptides and methods of use
AssigneesThe Medical College of Wisconsin, Inc., University of Virginia Patent Foundation
InventorsKaothara Oluwakemi Adeyanju, Jeffrey A. Medin, Robert Blake Hill, Lawrence G. Lum
Life of this patent
Estimating the term…
Abstract
The present disclosure provides soluble truncated mutant programmed death-ligand 1 (PD-L1) peptides. Polynucleotides and vectors encoding the soluble truncated mutant PD-L1 peptides are also provided. Further, methods of using the soluble truncated mutant peptides to promote differentiation of CD4+ effector T (Th1) cells into Foxp3+ regulatory T (Treg) cells are provided.
Claims15
A soluble mutant programmed death-ligand 1(PD-L1)peptide consisting essentially of SEQ ID NO:
- 1, wherein the PD-L1 peptide comprises one or more mutations selected from the group consisting of D9E, D105E, Y106W, R108M, Y39I, S1001, V51I, and combinations thereof, and wherein the position of each mutation is numbered relative to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.